Macrophage-associated SLAMF9 is a potential therapeutic target for glioma

Key Points

• SLAMF9 is identified as a potential therapeutic target for glioma.
• Key evidence indicates clinical significance of SLAMF9 in glioma patients, enhancing treatment options.
• This study employs an observational analysis examining the link between SLAMF9 and glioma outcomes in patients.
• This highlights the need for more targeted therapies, but results require further validation in diverse populations.